Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
作者信息
Khoury Rita, Chahine Claude, Ibrahim Rebecca, Khalife Nadine, Saleh Mohammad, Saleh Khalil
机构信息
International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
Department of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
出版信息
Future Oncol. 2023 Jun;19(17):1161-1163. doi: 10.2217/fon-2023-0318. Epub 2023 Jun 9.
PMID:37293779
Abstract
摘要
相似文献
1
Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma.
Future Oncol. 2023 Jun;19(17):1161-1163. doi: 10.2217/fon-2023-0318. Epub 2023 Jun 9.
2
Futibatinib (Lytgobi) for cholangiocarcinoma.
Trends Pharmacol Sci. 2023 Mar;44(3):190-191. doi: 10.1016/j.tips.2022.12.007. Epub 2023 Jan 24.
3
Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.
ESMO Open. 2023 Dec;8(6):102049. doi: 10.1016/j.esmoop.2023.102049. Epub 2023 Nov 2.
4
Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
Expert Opin Investig Drugs. 2022 Jan;31(1):125-131. doi: 10.1080/13543784.2022.2017882. Epub 2022 Jan 7.
5
Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
J Natl Compr Canc Netw. 2022 Apr 4;20(5):430-435. doi: 10.6004/jnccn.2021.7121.
6
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Expert Opin Investig Drugs. 2021 Apr;30(4):463-477. doi: 10.1080/13543784.2021.1900821. Epub 2021 Apr 11.
7
Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Liver Int. 2019 May;39 Suppl 1:32-42. doi: 10.1111/liv.14085. Epub 2019 Mar 24.
8
Futibatinib (Lytgobi) for cholangiocarcinoma.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e69-e70. doi: 10.58347/tml.2023.1674f.
9
Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress.
Curr Oncol. 2022 Oct 19;29(10):7925-7931. doi: 10.3390/curroncol29100626.
10
[Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
Bull Cancer. 2023 Oct;110(10):985-986. doi: 10.1016/j.bulcan.2023.06.005. Epub 2023 Jul 25.
引用本文的文献
1
Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma.
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):923-926. doi: 10.21037/hbsn-23-476. Epub 2023 Nov 15.
Zotero 插件